Debbie Rigby looks at the latest in research news
This review provides an expert opinion on dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes. Dapagliflozin and other SGLT2 inhibitors have the capacity to decrease hyperglycemia and visceral fat, components of the metabolic syndrome particularly associated with the progression of CV disease.
Expert Opinion on Pharmacotherapy 2017.
Grapefruit juice interacts with a number of drugs. This report details a ﬂow diagram to improve the prediction of the pharmacokinetic interactions and clinical relevance for affected drugs and recommends different courses of action for patient management.
Journal of Clinical Pharmacy and Therapeutics. 2017;42(2):125-127.
Medication discrepancies are common at hospital discharge, and medication reconciliation is widely endorsed as a preventive strategy. This study conducted in pharmacies in the Netherlands highlights problems faced by community pharmacists due to inadequate documentation at discharge. The patients’ lack of medication knowledge post-discharge was illustrated by the high need for patient education.
Journal of Clinical Pharmacy and Therapeutics. 2017;42(2):170-177.
The Systolic Blood Pressure Intervention Trial (SPRINT) was stopped early because of significantly lower risk of cardiovascular disease in participants randomised to a systolic blood pressure target of 120 mmHg (intensive) than in those randomized to 140 mmHg (standard). Significant risk reduction in cardiovascular outcomes (34%) and all-cause mortality (33%) was also identified in people aged 75 and older.
J Am Geriatr Soc. 2017;65(1):16-21.